01 April 2025 : Original article
Optimizing Tacrolimus Dosing During Hospitalization After Kidney Transplantation: A Comparative Model Analysis
Sangkyun Mok
ABCDEF 1, Sun Cheol Park ABDEF 2*, Sang Seob Yun AF 2, Young Jun Park AF 3, Dongin Sin CD 4, Jung K. Hyun CD 5
DOI: 10.12659/AOT.947768
Ann Transplant 2025; 30:e947768
Table 5 Baseline characteristics of the study population.
| Feature (variable) | Total (N=749) |
|---|---|
| Sex | |
| Male | 433 (57.8) |
| Female | 316 (42.2) |
| Age | 48.65±11.48, Range 16–75 |
| >55 | 489 (65.3) |
| 55~64 | 217 (29.0) |
| ≤65 | 43 (5.7) |
| BMI | 22.79±3.41, Range 22.79–38.8 |
| DM | |
| No | 513 (68.5) |
| Yes | 236 (31.5) |
| Hypertension | |
| No | 68 (9.1) |
| Yes | 681 (90.9) |
| Coronary artery disease | |
| No | 709 (94.7) |
| Yes | 40 (5.3) |
| ABOi | |
| No | 593 (79.2) |
| Yes | 156 (20.8) |
| Dialysis modality | |
| No | 174 (23.2) |
| Hemodialysis | 484 (64.6) |
| Peritoneal dialysis | 91 (12.1) |
| Donation type | |
| Living related | 359 (47.9) |
| Living unrelated | 13 (1.7) |
| Spouse | 192 (25.6) |
| Deceased | 185 (24.7) |
| Transplantation | |
| 1 | 672 (89.7) |
| 2 | 72 (9.6) |
| 3 | 5 (0.7) |
| Induction agent | |
| Simulect | 522 (69.7) |
| Antithymocyte globulin | 227 (30.3) |
| Rituximab | |
| No | 461 (61.5) |
| Yes | 288 (38.5) |
| Plasmapheresis | |
| No | 553 (73.8) |
| Yes | 196 (26.2) |
| Kidney weight (g) | 187.18±41.94, Range 104–430 |
| BUN (mg/dl) | 20.17±12.54, Range 4.3–104.2 |
| Creatinine (mg/dl) | 1.31±1.37, Range 0.37–15.40 |
| Admission duration (day) | 16.80±7.04, Range 11–119 |
| Tacrolimus trough level 11 day (ng/ml) | 8.26±2.64, Range 1.40–20.10 |
| Tacrolimus dose 11 day (Tablet) | 5.47±2.62, Range 0.5–17.0 |
| Tacrolimus trough level 12 day (ng/ml) | 8.23±2.51, Range 1.20–21.30 |
| Values are presented as number (%). DM – diabetes mellitus; BMI – body mass index; ABOi – ABO-incompatible; BUN – blood urea nitrogen. | |